Publication: 2819

Publication: 2819

Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

URL

Google Scholar

Citation:: J Clin Oncol vol 36 (suppl 4S) asbstr 614

Meeting Instance:: ASCO GI 2018
Year:: 2018
Type:: Abstract
Sub type:: Poster Discussion
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 2802 3167 3847

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: Eli Lilly and Company, Pfizer, Bristol-Myers Squibb
Grants:: U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, CCSRI 021039

Corr. Author:
Authors:: Frank A. Sinicrope Qian Shi Fabienne Hermitte Erica N. Heying Al B. Benson Sharlene Gill Richard M. Goldberg Morton S. Kahlenberg Suresh G. Nair Anthony F. Shields Daniel J. Sargent Jérôme Galon Steven R. Alberts

Networks:

Study: NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: